Drug Development Pipeline
Anagram Therapeutics (formerly Synspira Therapeutics)
This program is studying ANG003 (formerly SNSP003), a non-porcine (not pig-derived) enzyme replacement therapy for individuals with CF who have exocrine pancreatic insufficiency. It is a man-made version of a lipase enzyme taken from bacteria, and it does not contain any animal products.
ANG003 may improve dosing convenience by reducing pill burden compared to current porcine-based pancreatic enzyme replacement therapies (PERT). ANG003 is also being developed in a formulation for pediatric and adult patients who are unable to swallow capsules.
Laboratory studies to develop and test this compound are underway.
This program is sponsored by Anagram Therapeutics (formerly known as Synspira Therapeutics) and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More